This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Peregrine Pharma Is Wasting Money On A Placebo Cancer Drug

TUSTIN, Calif. ( TheStreet) -- Peregrine Pharmaceuticals (PPHM - Get Report) disclosed new pancreatic cancer study results Wednesday showing its cancer drug bavituximab behaves very much like a placebo.

In a phase II study of 70 patients with advanced pancreatic cancer, the combination of bavituximab and gemcitabine prolonged survival by just 12 days over gemcitabine alone. Peregrine didn't disclose a p value for the survival analysis, so assume it was large and definitely not statistically significant.

Neither the 5.8 month median overall survival in the bavituximab-gemcitabine arm of Peregrine's phase II study nor 5.2 months in the gemcitabine arm was any better than the historical 5-6 month survival typically seen when pancreatic cancer patients are treated with gemcitabine alone.

In Celgene's (CELG - Get Report) recent phase III study, which enrolled more than 800 patients, the combination of Abraxane plus gemcitabine yielded a median overall survival of 8.5 months compared to 6.7 months for gemcitabine alone.

Overall survival was the primary endpoint of the bavituximab pancreatic cancer study, which dulls the clinical meaning of the response rate benefit touting by Peregrine in Wednesday's press release.

Patients treated with bavituximab-gemcitabine had a 28% tumor response rate compared to 13% for patients treated with gemcitabine alone. Peregrine fails to note if the response rate difference was statistically significant, or if response rates were confirmed by independent review.

Peregrine has a habit of releasing unverified response rate data from bavituximab studies, only to see those response rates nullified by independent review.

And of course, Peregrine's credibility was shot when it was forced to rescind last year's bavituximab lung cancer data due to improper study conduct.

In a statement Wednesday, Peregrine said it hoped to find subsets of pancreatic cancer patients where bavituximab may work better. Data mining negative study results is the last bastion of hope for desperate drug developers.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CELG $104.21 -0.72%
PPHM $0.36 -2.60%
AAPL $95.36 1.80%
FB $117.87 -0.59%
GOOG $695.88 -0.33%


Chart of I:DJI
DOW 17,768.26 -122.90 -0.69%
S&P 500 2,064.24 -17.19 -0.83%
NASDAQ 4,773.3620 -44.2320 -0.92%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs